Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PJ009 (recombinant teduglutide) in short bowel syndrome requiring parenteral nutrition
CTR20241372Phase 3Active
- Sponsor
- Chongqing Paijin Biotechnology
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of teduglutide in short bowel syndrome (SBS), sponsored by Chongqing Paijin Biotechnology. Started Jul 2024; status: active.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on CTR20241372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241372.